What we do SMS Pharmaceuticals Ltd manufactures active pharmaceutical ingredients and intermediates with FDA-compliant facilities serving global regulated markets. |
Founded in 1,987 |
Market share Leader in key APIs with strong global presence in regulated markets; commanding significant market share in multiple therapeutic segments. |
Problem solved Addresses global demand for high-quality, compliant pharmaceutical ingredients ensuring supply chain reliability and therapeutic efficacy. |
Top clients or who we serve Serves large and mid-sized pharmaceutical companies globally across regulated markets including North America, Europe, and Asia; primarily B2B. |
Key management Chairman & Managing Director: Ramesh Babu Potluri; Executive Director: Vamsi Krishna Potluri. |
Our journey and innovations Established in 1987; expanded with USFDA-approved plants; demerged semi-regulated units to subsidiary; launched Asia's largest automated ibuprofen facility; expanded product pipeline and R&D focus. |
Where we operate Mainly India with exports to over 75 countries including North America, Europe, and Asia. |
Top products or what we offer APIs across anti-diabetic, anti-epileptic, anti-inflammatory, anti-retroviral, anti-ulcer, anti-migraine, and more. |
Top brands Leading APIs in anti-diabetic and anti-retroviral segments; Asia's largest dedicated ibuprofen production block; VKT Pharma associate enhances portfolio. |
Raw materials needed Raw materials include chemical intermediates and specialty chemicals required for API synthesis. |
Raw materials supplier Sourced globally including low dependency on China due to backward integration initiatives. |
Recurring vs cyclical contribution Revenue primarily from recurring sales with growth driven by capacity expansion and new product launches. |
Our industry position Strong global and domestic market positioning with regulatory approvals supporting leadership in multiple therapeutic APIs. |
Financial highlights FY25 net revenue ₹782.75 crore; PAT ₹69.14 crore; EBITDA margin around 20-21%; consistent year-on-year growth. |
Geographical revenue split Exports constitute approximately 69% of revenue; domestic sales 31%. |
Order book - |
Whats driving growth Volume growth in key APIs, operating leverage, strategic capex, new product launches, and backend integration. |
Our future plans ₹280 crore capex ongoing to expand capacity and add new APIs aiming for 20% revenue growth by FY27. |
Our green promise Committed to environmental sustainability, energy conservation, and employee health and safety through continuous improvements. |
Our people and values 1,500+ employees with focus on skill development, safety, diversity, and fostering innovation. |
Key challenges ahead Market price pressures, regulatory compliances, competition, and raw material fluctuating costs. |
Interesting facts Launched Asia's largest automated ibuprofen production facility; strategic JV in Spain; multiple USFDA audits passed. |
Risks and strategy Mitigates regulatory risks via compliance; supply chain risks through backward integration; strategic R&D investment for sustainable growth. |
